HK18094A - Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents - Google Patents

Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents Download PDF

Info

Publication number
HK18094A
HK18094A HK180/94A HK18094A HK18094A HK 18094 A HK18094 A HK 18094A HK 180/94 A HK180/94 A HK 180/94A HK 18094 A HK18094 A HK 18094A HK 18094 A HK18094 A HK 18094A
Authority
HK
Hong Kong
Prior art keywords
particles
ferromagnetic
contrast agents
nmr
ferromagnetic material
Prior art date
Application number
HK180/94A
Other languages
German (de)
English (en)
Inventor
Trond Jacobsen
Jo Klaveness
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10558866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK18094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of HK18094A publication Critical patent/HK18094A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dispersion Chemistry (AREA)
  • Signal Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Compounds Of Iron (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubricants (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Soft Magnetic Materials (AREA)

Claims (13)

1. Utilisation de particules de matière ferromagnétique pour la fabrication d'un agent de contraste de résonance magnétique nucléaire destiné à être utilisé dans un procédé de diagnostic pratiqué sur l'organisme de l'homme ou de l'animal, ce procédé consistant à engendrer une image qui dépend de T2 et à effectuer un diagnostic en utilisant cette image.
2. Utilisation, suivant la revendication 1, de particules d'une matière ferromagnétique enrobée ou revêtue d'une matrice non ferromagnétique ou revêtue d'un polymère non biodégradable et acceptable biologiquement.
3. Utilisation, suivant la revendication 1 ou 2, de ces particules et d'un agent augmentant la viscosité et/ou d'un agent tensio-actif pour la préparation de l'agent de contraste.
4. Utilisation, suivant l'une quelconque des revendications 1 à 3, de particules d'une matière ferromagnétique ayant une dimension comprise entre 0,01 et 0,6 micron.
5. Utilisation, suivant la revendication 4, de particules d'une matière ferromagnétique ayant une dimension de 0,01 à 0,02 micron.
6. Utilisation, suivant l'une quelconque des revendications 1 à 3, de particules d'une matière ferromagnétique ayant une dimension comprise entre 0,002 et 50 microns.
7. Utilisation, suivant l'une quelconque des reven dications 4 à 6, de particules non revêtues d'une matière ferromagnétique.
8. Utilisation, suivant l'une quelconque des revendications 1 à 7, de particules d'une matière ferromagnétique qui sont des particules d'oxyde de fer magnétique.
9. Utilisation, suivant la revendication 8, de particules d'un ferrite.
10. Utilisation, suivant la revendication 8, de particules de magnétite ou de gamma-fe203.
11. Utilisation, suivant l'une quelconque des revendications 1 à 10, pour la préparation de l'agent sous une forme adaptée à l'administration parentérale.
12. Utilisation, suivant la revendication 4, pour la préparation d'un agent de contraste spécifique au tissu.
13. Utilisation, suivant la revendication 1, de particules ayant une dimension maximum comprise entre 0,1 et 20 microns et ayant une teneur en substance ferromagnétique de 0,5 à 50 % en poids.
HK180/94A 1984-03-29 1994-03-03 Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents HK18094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848408127A GB8408127D0 (en) 1984-03-29 1984-03-29 Contrast agents
PCT/NO1985/000017 WO1985004330A1 (fr) 1984-03-29 1985-03-28 Utilisation de particules ferromagnetiques dans des agents de contraste pour la formation d'image par resonance magnetique nucleaire (nmr), et agents de contraste

Publications (1)

Publication Number Publication Date
HK18094A true HK18094A (en) 1994-03-11

Family

ID=10558866

Family Applications (1)

Application Number Title Priority Date Filing Date
HK180/94A HK18094A (en) 1984-03-29 1994-03-03 Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents

Country Status (13)

Country Link
US (1) US4863715A (fr)
EP (1) EP0177545B2 (fr)
JP (1) JPH066538B2 (fr)
AT (1) ATE61001T1 (fr)
AU (1) AU568740B2 (fr)
DE (1) DE3581871D1 (fr)
DK (1) DK171526B1 (fr)
FI (1) FI85442C (fr)
GB (1) GB8408127D0 (fr)
HK (1) HK18094A (fr)
NL (1) NL960016I2 (fr)
NO (2) NO173429C (fr)
WO (1) WO1985004330A1 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US5618514A (en) * 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
US5720939A (en) * 1985-08-15 1998-02-24 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using magnetically responsive-particles
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
DE3700911C2 (de) * 1986-01-17 2001-05-17 West Pharm Serv Drug Res Ltd System zur Zuführung eines Arzneimittels oder eines Diagnostikums
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5248492A (en) * 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US4951675A (en) * 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US5160726A (en) * 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
FR2612400A1 (fr) * 1987-03-16 1988-09-23 Centre Nat Rech Scient Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US5154179A (en) * 1987-07-02 1992-10-13 Medical Magnetics, Inc. Device construction and method facilitating magnetic resonance imaging of foreign objects in a body
DE3723310A1 (de) * 1987-07-15 1989-01-26 John Urquhart Pharmazeutisches praeparat und verfahren zu seiner herstellung
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JPH076765B2 (ja) * 1988-06-23 1995-01-30 株式会社日立メディコ 非破壊断面形状検査装置
GB8817137D0 (en) * 1988-07-19 1988-08-24 Nycomed As Compositions
ATE139431T1 (de) 1988-08-04 1996-07-15 Advanced Magnetics Inc Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri
GB8819753D0 (en) * 1988-08-19 1988-09-21 Nycomed As Apparatus
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
GB8916780D0 (en) 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
CA2075994A1 (fr) 1990-02-15 1991-08-16 Lee Josephson Sterilisation de filtres pour la production d'agents de contraste colloidaux et superparamagnetiques utilises en irm
US5190744A (en) * 1990-03-09 1993-03-02 Salutar Methods for detecting blood perfusion variations by magnetic resonance imaging
US5494655A (en) * 1990-03-09 1996-02-27 The Regents Of The University Of California Methods for detecting blood perfusion variations by magnetic resonance imaging
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
DE69131721T2 (de) * 1990-04-10 2000-03-02 Imarx Pharmaceutical Corp., Tucson Polymere als Kontrastmittel bei magnetischer Resonanz
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
GB9020075D0 (en) * 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US6919067B2 (en) 1991-09-13 2005-07-19 Syngenix Limited Compositions comprising a tissue glue and therapeutic agents
GB9120508D0 (en) * 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
JPH07501331A (ja) * 1991-11-19 1995-02-09 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 改良された診断用の造影のためのゲル粒子造影剤
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
EP0580878B1 (fr) * 1992-06-01 1996-01-10 BASF Aktiengesellschaft Application de dispersions de particules magnéto-ioniques aux fins d'agents de contrast pour I.M.N.
ES2130406T5 (es) * 1992-08-05 2003-12-16 Meito Sangyo Kk Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
ATE156706T1 (de) * 1993-03-17 1997-08-15 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
NL9401518A (nl) * 1994-09-19 1996-05-01 Cordis Europ MR-zichtbare catheter met in uitgehard materiaal opgenomen deeltjesvormig magnetiseerbaar materiaal.
US5728079A (en) * 1994-09-19 1998-03-17 Cordis Corporation Catheter which is visible under MRI
DE19516323C2 (de) * 1995-04-27 1997-02-27 Dirk Dipl Chem Guenther Verfahren zur Herstellung von magnetisierbaren Dispersionen und deren Verwendung
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
CA2242647A1 (fr) 1996-01-10 1997-07-17 Amersham Health As Milieu de contraste
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
CN1151846C (zh) * 1996-08-05 2004-06-02 舍林公开股份有限公司 核磁共振断层扫描成像用造影剂的制备方法
WO1999012578A1 (fr) * 1997-09-10 1999-03-18 Yale University Dosimetrie par rayonnements avec composes detectables par resonance magnetique
WO1999052564A1 (fr) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Procede
AU765085B2 (en) 1998-05-11 2003-09-11 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific T cells
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US6296604B1 (en) * 1999-03-17 2001-10-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6355225B1 (en) 1999-10-05 2002-03-12 Wm. Marsh Rice University Tda Research, Inc. Fullerene contrast agent for magnetic resonance imaging and spectroscopy
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US20020177769A1 (en) * 2001-04-23 2002-11-28 The Regents Of The University Of California Method and apparatus for locating cells in the body by measuring magnetic moments
US7018849B2 (en) * 2002-01-15 2006-03-28 Piasio Roger N Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
US20040225213A1 (en) 2002-01-22 2004-11-11 Xingwu Wang Magnetic resonance imaging coated assembly
US7162302B2 (en) 2002-03-04 2007-01-09 Nanoset Llc Magnetically shielded assembly
GB0215185D0 (en) * 2002-07-01 2002-08-07 Genovision As Binding a target substance
JP2005531643A (ja) * 2002-07-02 2005-10-20 ユニベルシテア、メディッシュ、セントラム、ユトレヒト 直径が少なくとも１マイクロメートルの粒子を含んでなる走査懸濁液
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7803352B2 (en) * 2003-03-07 2010-09-28 John Steele Fisher Method for continuous visualization of a blood clot or plaque in body lumen
US20040175329A1 (en) * 2003-03-07 2004-09-09 Fisher John Steele Method for continuous visualization of a body lumen
CA2425795C (fr) * 2003-04-15 2012-03-27 Sylvain Martel Methode et dispositif de propulsion et de guidage d'un microrobot dans un vaisseau sanguin
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
EP1557151A1 (fr) * 2004-01-22 2005-07-27 F. Hoffmann-La Roche Ag Forme de dosage solide
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
JP4322781B2 (ja) * 2004-11-08 2009-09-02 富士フイルム株式会社 撮像装置
US8669236B2 (en) 2005-05-12 2014-03-11 The General Hospital Corporation Biotinylated compositions
US20070025918A1 (en) * 2005-07-28 2007-02-01 General Electric Company Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization
US20070098640A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US9149545B2 (en) * 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
EP1991577A2 (fr) 2006-01-31 2008-11-19 Parkinson, John F. Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
EP2079483A4 (fr) 2006-07-29 2010-10-20 Robert Lamar Bjork Jr Medicament therapeutique d'anticorps monoclonal bispécifique (specifique a la fois a cd3 et cd11b)
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2277181B1 (fr) * 2008-04-16 2017-08-30 StemCell Technologies Inc. Particules magnétiques
GB0820309D0 (en) * 2008-11-06 2008-12-17 Middlesex University Higher Ed Detection of cancer
EP2390661B1 (fr) 2010-05-02 2015-06-24 Miltenyi Biotec GmbH Supports d'ancrage/capture pour sélectionner ou analyser une cellule CHO en fonction d'un produit sécrété par la cellule CHO
US9655977B2 (en) 2012-08-31 2017-05-23 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
EP2955521A1 (fr) 2014-06-11 2015-12-16 Centre Hospitalier Universitaire Vaudois (CHUV) Procédés pour séparer des cellules
EP3412303A1 (fr) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Pharmacocinétique améliorée et ciblage du récepteur cholecystokinin-2 (cck2r) pour le diagnostic et la thérapie

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592185A (en) * 1967-04-18 1971-07-13 Yeda Res & Dev Ferromagnetic contrast media and method of use
GB1339537A (en) * 1969-12-03 1973-12-05 Yeda Res & Dev Diagnostic and/or therapeutic compositions
SE431214B (sv) * 1977-06-02 1984-01-23 Klaus H Mosbach Sett att framstella magnetiska polymerpartiklar som berare av en foretredesvis biologiskt aktiv substans
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
EP0093757A1 (fr) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Nanosphere ou nanoparticule a sensibilite magnetique, pouvant etre administree de maniere intravasculaire, son procede de production et son utilisation
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
DE3219832A1 (de) * 1982-05-26 1983-12-01 Bruker Medizintechnik Gmbh, 7512 Rheinstetten Verfahren zur nicht-invasiven ermittlung von messwerten innerhalb eines lebenden koerpers
WO1984002643A1 (fr) * 1983-01-10 1984-07-19 Robert Thomas Gordon Procede d'amelioration de mise en image a resonance magnetique nucleaire et son utilisation a des fins diagnostiques
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
CA1242643A (fr) * 1983-08-12 1988-10-04 Eric T. Fossel Imagerie medicale par rmn faisant appel a des reactifs provoquant des deplacements chimiques
SE463651B (sv) † 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents

Also Published As

Publication number Publication date
DE3581871D1 (de) 1991-04-04
JPH066538B2 (ja) 1994-01-26
NO173429B (no) 1993-09-06
US4863715A (en) 1989-09-05
FI85442C (fi) 1992-04-27
EP0177545B2 (fr) 2002-10-23
DK528385D0 (da) 1985-11-15
ATE61001T1 (de) 1991-03-15
WO1985004330A1 (fr) 1985-10-10
EP0177545B1 (fr) 1991-02-27
NO173429C (no) 1993-12-22
FI854488A0 (fi) 1985-11-14
NO854765L (no) 1985-11-28
JPS61501633A (ja) 1986-08-07
DK528385A (da) 1985-11-15
GB8408127D0 (en) 1984-05-10
EP0177545A1 (fr) 1986-04-16
NL960016I2 (nl) 1996-12-02
FI854488L (fi) 1985-11-14
AU568740B2 (en) 1988-01-07
DK171526B1 (da) 1996-12-23
NO1994016I1 (no) 1994-09-05
NL960016I1 (nl) 1996-10-01
FI85442B (fi) 1992-01-15
AU4215185A (en) 1985-11-01

Similar Documents

Publication Publication Date Title
EP0177545B1 (fr) Utilisation de particules ferromagnetiques dans des agents de contraste pour la formation d'image par resonance magnetique nucleaire (nmr), et agents de contraste
US4770183A (en) Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5628983A (en) Squid magnetometry using paramagnetic metal chelates
US4827945A (en) Biologically degradable superparamagnetic materials for use in clinical applications
US5069216A (en) Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US4951675A (en) Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
RU2137501C1 (ru) Применение физиологически допустимого, корпускулярного ферримагнитного или ферромагнитного материала, способ формирования магнитометрического изображения, процесс обнаружения изменений, применение физиологически допустимых парамагнитных, сверхпарамагнитных, ферромагнитных или ферримагнитных частиц, устройство формирования изображения
US5023072A (en) Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract
AU624132B2 (en) Contrast agents for magnetic resonance imaging
US5219554A (en) Hydrated biodegradable superparamagnetic metal oxides
Pouliquen et al. Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: contribution of microencapsulation to improved biodistribution
JP2002508687A (ja) 磁気共鳴（ｍｒ）イメージング剤の生体外分極を含むオーバーハウザー磁気共鳴画像（ｏｒｍｉ）法
JPH07505638A (ja) 磁気共鳴イメージングの方法および組成物
Gervits Relaxation Properties of Contrast Media for MRI Based on Iron Oxide Nanoparticles in Different Magnetic Fields

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20050327